{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T17:38:36Z","timestamp":1768930716621,"version":"3.49.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Ichthyoses, a group of skin cornification disorders caused by protein and lipid abnormalities that disrupt epidermal functions, are mainly characterized by generalized scaling. This study is the first to report the use of Vunakizumab, China\u2019s first self-developed anti-IL-17A monoclonal antibody, in treating ichthyosis. We presented a case of a 4-year-old boy with epidermolytic ichthyosis (EI) due to a <jats:italic>KRT1<\/jats:italic> gene mutation. Since birth, he has presented with generalized erythema, desquamation, and blister formation at the extremities. Then, palmoplantar hyperkeratosis gradually emerged, accompanied by severe pruritus. After a three-month treatment with Vunakizumab, symptoms alleviated significantly and inflammatory factor levels normalized. This not only shows the great potential of Vunakizumab in treating ichthyosis but also paves the way for further research on anti-IL-17A therapies for skin cornification disorders, offering treatment options for ichthyosis patients.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1574255","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T04:10:28Z","timestamp":1747368628000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["First successful treatment of epidermolytic Ichthyosis with Vunakizumab: A Case Report"],"prefix":"10.3389","volume":"16","author":[{"given":"Wenjie","family":"Cheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaolan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peiyi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiawen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhirong","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41572-022-00412-3","article-title":"Ichthyosis","volume":"9","author":"Guti\u00e9rrez-Cerrajero","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17203","article-title":"Management of congenital ichthyoses: European guidelines of care, part one","volume":"180","author":"Mazereeuw-Hautier","year":"2019","journal-title":"Br J Dermatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s13023-022-02430-6","article-title":"New developments in the molecular treatment of ichthyosis: review of the literature","volume":"17","author":"Joosten","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00718-8","article-title":"Treatments for non-syndromic inherited ichthyosis, including emergent pathogenesis-related therapy","volume":"23","author":"Hasbani","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02110-8","article-title":"Vunakizumab: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"B6","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0923-1811(02)00040-3","article-title":"Keratin 1 and keratin 10 mutations causing epidermolytic hyperkeratosis in Chinese patients","volume":"29","author":"Sun","year":"2002","journal-title":"J Dermatol Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.11.020","article-title":"Revised nomenclature and classification of inherited ichthyoses: results of the First\u00a0Ichthyosis Consensus Conference in Sor\u00e8ze 2009","volume":"63","author":"Oji","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20096","article-title":"Epidermolytic ichthyosis: Clinical spectrum and burden of disease in a large German cohort","volume":"39","author":"Frommherz","year":"2025","journal-title":"J Eur Acad Dermatol Venereology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1001\/jamadermatol.2021.4242","article-title":"The\u00a0genomic and phenotypic landscape of ichthyosis: an analysis of 1000 kindreds","volume":"158","author":"Sun","year":"2022","journal-title":"JAMA Dermatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.11.10.3539","article-title":"Coiled-coil trigger motifs in the 1B and 2B rod domain segments are required for the stability of keratin intermediate filaments","volume":"11","author":"Wu","year":"2000","journal-title":"Mol Biol Cell"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.10096.x","article-title":"Expanding the keratin mutation database: novel and recurrent mutations and genotype\u2013phenotype correlations in 28 patients with epidermolytic ichthyosis","volume":"164","author":"Arin","year":"2011","journal-title":"Br J Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.v8.12","article-title":"A novel KRT1 c. 1433A> G p.(Glu478Gly) mutation in a newborn with epidermolytic ichthyosis","volume":"8","author":"Caroppo","year":"2020","journal-title":"Clin Case Reports"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2299","article-title":"Expanding the clinical and genetic spectrum of KRT1, KRT2 and KRT10 mutations in keratinopathic ichthyosis","volume":"96","author":"Hotz","year":"2016","journal-title":"Acta dermato-venereologica"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08244.x","article-title":"Congenital ichthyosiform erythroderma mimicking ichthyosis bullosa of Siemens","volume":"158","author":"Tsubota","year":"2008","journal-title":"Br J Dermatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2013.03.001","article-title":"Mild phenotype of epidermolytic hyperkeratosis mimicking ichthyosis bullosa of Siemens is related to specific mutation in 2B domain of KRT1","volume":"70","author":"Sung","year":"2013","journal-title":"J Dermatol Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/000155501750376221","article-title":"Phenotypic\/genotypic correlations in patients with epidermolytic hyperkeratosis and the effects of retinoid therapy on keratin expression","volume":"81","author":"Virtanen","year":"2001","journal-title":"Acta Derm Venereol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.08.027","article-title":"Profiling immune expression to consider repurposing therapeutics for the ichthyoses","volume":"139","author":"Paller","year":"2019","journal-title":"J Invest Dermatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.03.021","article-title":"Ichthyosis molecular fingerprinting shows profound T(H)17 skewing and a unique barrier genomic signature","volume":"143","author":"Malik","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.07.019","article-title":"An IL-17\u2013dominant immune profile is shared across the major orphan forms of ichthyosis","volume":"139","author":"Paller","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20033","article-title":"Exploring Th17-related inflammation in AP1B1-associated KIDAR syndrome and potential therapeutic implications of secukinumab","volume":"39","author":"Pan","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1165\/ajrcmb.26.6.4757","article-title":"Interleukin-17 stimulates the expression of interleukin-8, growth-related oncogene-alpha, and granulocyte-colony-stimulating factor by human airway epithelial cells","volume":"26","author":"Jones","year":"2002","journal-title":"Am J respiratory Cell Mol Biol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13075-018-1551-x","article-title":"Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)","volume":"20","author":"Nash","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2015.2939","article-title":"IL-17 promotes keratinocyte proliferation via the downregulation of C\/EBP\u03b1","volume":"11","author":"Ma","year":"2016","journal-title":"Exp Ther Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.3390\/ijms21041275","article-title":"Interleukin-17A and keratinocytes in psoriasis","volume":"21","author":"Furue","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3794","article-title":"Targeting IL-17 and TH17 cells in chronic inflammation","volume":"11","author":"Miossec","year":"2012","journal-title":"Nat Rev Drug discovery"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.07.008","article-title":"Frequency of HLA-DR+ CD38hi T cells identifies and quantifies T-cell activation in hemophagocytic lymphohistiocytosis, hyperinflammation, and immune regulatory disorders","volume":"153","author":"Nguyen","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.2019.17.issue-1","article-title":"Biologic therapy targeting IL-17 ameliorates a case of congenital ichthyosiform cornification disorder","volume":"17","author":"Haiges","year":"2019","journal-title":"J Dtsch Dermatol Ges"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-022-02325-3","article-title":"Secukinumab responses vary across the spectrum of congenital ichthyosis in adults","volume":"315","author":"Lefferdink","year":"2023","journal-title":"Arch Dermatol Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae420","article-title":"Biologics in congenital ichthyosis: are they effective","volume":"192","author":"Mazereeuw-Hautier","year":"2025","journal-title":"Br J Dermatol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14389","article-title":"Inherited ichthyosis and fungal infection: an update on pathogenesis and treatment strategies","volume":"19","author":"Miao","year":"2021","journal-title":"J der Deutschen Dermatologischen Gesellschaft"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21687","article-title":"Distinct skin microbiome community structures in congenital ichthyosis","volume":"187","author":"Tham","year":"2022","journal-title":"Br J Dermatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1294416","article-title":"Short-term risk and long-term incidence rate of infection and Malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"14","author":"Wu","year":"2023","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.09.031","article-title":"Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: A randomized, double-blind, placebo-controlled phase 3 trial","volume":"92","author":"Yan","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jaad.2022.01.005","article-title":"A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis","volume":"87","author":"Zhang","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40257-025-00928-w","article-title":"Next-generation anti-IL-17 agents for psoriatic disease: A pipeline review","volume":"21","author":"Kim","year":"2025","journal-title":"Am J Clin Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1574255\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T04:10:29Z","timestamp":1747368629000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1574255\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":35,"alternative-id":["10.3389\/fimmu.2025.1574255"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1574255","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]},"article-number":"1574255"}}